Michel Vounatsos, Biogen CEO (Biogen via YouTube)
November 2, 2020 08:34 AM ESTUpdated 04:13 PM
FDA+

Bio­gen dodges a bul­let in its con­tro­ver­sial quest to gain an ap­proval for their ex­per­i­men­tal Alzheimer’s drug ad­u­canum­ab

John Carroll

Editor & Founder

David Knop­man, a pro­fes­sor of neu­rol­o­gy at the Mayo Clin­ic and a long­time ex­pert on treat­ing Alzheimer’s, was re­cused from his reg­u­lar pan­el seat on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times